Drug Reference
Phentermine / Topiramate
Centrally acting antiobesity products
Fact box
- Therapeutic class
- Centrally acting antiobesity products
Brand names
Qsymia
Available as
7.5 MG · Extended Release Oral Capsule3.75 MG · Extended Release Oral Capsule15 MG · Extended Release Oral Capsule11.25 MG · Extended Release Oral Capsule
Multi-ingredient product
PhentermineTopiramate
This medicine contains more than one active ingredient. To avoid attributing one component’s information to the whole product, structured label sections aren’t shown here — see the component pediatric notes below and the full combination label on DailyMed.
Current FDA labels (DailyMed)
- PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE CAPSULE [DR.REDDYS LABORATORIES INC]
- PHENTERMINE AND TOPIRAMATE CAPSULE, EXTENDED RELEASE [PRASCO LABORATORIES]
- QSYMIA (PHENTERMINE AND TOPIRAMATE) CAPSULE, EXTENDED RELEASE [VIVUS LLC]
- PHENTERMINE AND TOPIRAMATE CAPSULE, EXTENDED RELEASE [TEVA PHARMACEUTICALS, INC.]
Authoritative sources
Reference only — not clinical advice. Verify against current FDA labeling and consult a licensed provider. About half of pediatric drug use is off-label and is not reflected in FDA labels; absence of pediatric information does not mean a medicine is unused or unsafe in children.